ABSTRACT

Ovarian cancer remains the most lethal gynaecological cancer in the world. The common cytoreductive surgery, accompanied by platinum-based cancer treatment, has still been used to treat ovarian cancer. Despite the fact that the major group of cases are initially platinum- sensitive, they will over time gain platinum resistance, and platinum-resistant cases have a low response to second-line chemotherapy. In addition, at the molecular level, ovarian cancer is thought to be a complex and heterogeneous disease. A more efficient and less harmful therapy strategy for ovary cancer is molecular targeted treatment. Presently, anti-vegf monoclonal antibodies and parp (poly-adp-ribose polymerase) inhibitors are the two main types of approved and most efficient targeted drugs for ovaria cancer.Potential therapeutic targets include the ras/raf/mer pathway, the pi3k/akt pathway, folate receptor alpha, and immune checkpoints. In this article, relevant clinical trials examining the efficacy and safety of potential targets in ovarian cancer, the major difficulties in targeted therapy, and suggested potential solutions to enhance the therapeutic effects were discussed. Due to advancements in next-generation sequencing technology and molecular biology techniques, we are now able to identify more targetable molecular alterations in a larger group of patients with ovarian cancer. The goal of personalised therapy will be closer to being attained, and the outcome for patients with ovarian cancer will be improved by focusing on these molecular characteristics.
Publication date: 01/12/2023

https://ijbpas.com/pdf/2023/December/MS_IJBPAS_2023_7581.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.12.7581